|Articles|May 4, 2021
Isolation of Tumor-Infiltrating Lymphocytes from Dissociated Tumor Cells
Author(s)BioIVT
Tumor-infiltrating lymphocytes may hold the key to treating solid tumors with cell therapies, and BioIVT’s DTC product line is a great source for TILs. In this white paper, you’ll read about defining what TILs are, their potential therapeutic applications, the characterization of BioIVT’s current donor pool by TIL content and the frequency of TILs by tumor tissue type.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Charles River Incubator Cohort to Accelerate CGT Development
2
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
3
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
4
New Cord Blood Stem Cell Approval Alters Biopharma Manufacturing Priorities
5
